372320 — Curocell Balance Sheet
0.000.00%
- KR₩592bn
- KR₩619bn
Annual balance sheet for Curocell, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | — | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 41,143 | 40,979 | 7,126 | 39,917 | 9,581 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 22.1 | 616 | 2,183 | 746 | 168 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 41,446 | 64,161 | 41,397 | 42,787 | 13,047 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9,880 | 17,809 | 46,104 | 61,242 | 55,450 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 51,473 | 82,163 | 87,988 | 104,969 | 72,021 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 45,922 | 84,837 | 106,648 | 3,270 | 38,751 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 49,050 | 94,399 | 135,586 | 45,870 | 42,567 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 2,424 | -12,236 | -47,598 | 59,100 | 29,454 |
| Total Liabilities & Shareholders' Equity | 51,473 | 82,163 | 87,988 | 104,969 | 72,021 |
| Total Common Shares Outstanding |